Takeda Pharmaceutical (NYSE:TAK) Shares Down 2.4%

Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) traded down 2.4% on Thursday . The stock traded as low as $13.84 and last traded at $13.85. 333,358 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 1,826,837 shares. The stock had previously closed at $14.19.

Takeda Pharmaceutical Stock Down 2.1 %

The firm has a market cap of $43.96 billion, a price-to-earnings ratio of 21.05, a P/E/G ratio of 3.38 and a beta of 0.54. The firm's fifty day moving average is $14.51 and its two-hundred day moving average is $14.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion during the quarter. On average, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.

Insider Buying and Selling at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company's stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total value of $29,999,994.30. Following the completion of the sale, the insider now directly owns 3,755,583 shares of the company's stock, valued at approximately $30,420,222.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.04% of the stock is owned by corporate insiders.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. Capital Research Global Investors lifted its stake in Takeda Pharmaceutical by 3.6% during the fourth quarter. Capital Research Global Investors now owns 14,297,805 shares of the company's stock valued at $204,030,000 after buying an additional 503,446 shares in the last quarter. Morgan Stanley lifted its position in shares of Takeda Pharmaceutical by 9.5% in the third quarter. Morgan Stanley now owns 5,233,281 shares of the company's stock worth $80,959,000 after purchasing an additional 455,729 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Takeda Pharmaceutical by 8.7% during the second quarter. Goldman Sachs Group Inc. now owns 4,731,724 shares of the company's stock valued at $74,335,000 after acquiring an additional 380,221 shares in the last quarter. Macquarie Group Ltd. raised its position in Takeda Pharmaceutical by 1.9% during the first quarter. Macquarie Group Ltd. now owns 3,908,735 shares of the company's stock valued at $64,416,000 after acquiring an additional 72,745 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Takeda Pharmaceutical by 22.8% during the second quarter. Renaissance Technologies LLC now owns 3,650,000 shares of the company's stock valued at $57,341,000 after acquiring an additional 676,600 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.